QT Vascular said it acquired a new technology platform created by an undisclosed developer in Israel called Java that it plans to develop as an aortic valvuloplasty balloon for transcatheter aortic valve implants.
Transmedics said surgeons in Australia used its organ care system to preserve and assess a trio of hearts from donors whose organs had stopped beating, before the hearts were successfully transplanted.
On the heels of CE Mark approval in Europe, ReFlow Medical announced FDA clearance for its Wingman35 crossing catheter and said it has already been used in California vascular clinics.
Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it’s developing.
San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million with the SEC in 2013.
Gynesonics said it won an FDA investigational device exemption for its VizAblate system with an outpatient option for treating symptomatic uterine fibroids.
Life Spine launched a new division called Centric Medical, after receiving FDA marketing clearance for its Tarsa-Link system for internal bone fixation of fractures, fusions, and osteotomies in the foot and ankle.
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
Sensory Medical shook a leg on a 2nd tranche of funding since receiving FDA clearance last spring for its device to relieve symptoms of restless legs syndrome, reporting $1.4 million in fresh funding on the heels of a $1 million tranche in June.
Medrobotics said it closed on $20 million in new funding in a preferred stock sale to prior backers as plans to expand its commercial footprint in Europe.
Raynham, Mass.-based Medrobotics also said that it’s "met all applicable FDA requirements" to distribute its Flex Retractor in the U.S.
MassDevice Network
@MassDevice
LinkedIn
YouTube